JP Morgan 2024 Health Care Week Recap. 240117

이라는 제목으로 그냥 어디 미국 기업에서 메일 보내줬길래 그냥 올려 봄 😂

 

내 개인 네이버메일 정보는 또 어디서 흘러간 걸까.... 몇 년 전부터 거의 gmail 쓰고 있는데 🤔

그래도 미국 제약 주식에 좀 관심 있어서 읽어보긴 했다.

 

각종 잡저널, 무슨 리뷰 어쩌고, 제품 홍보 등 스팸 메일 창고로 전락해버린 내 네이버 메일에

그래도 읽을 만한 정보를 준 메일은 오랜만 ㅋㅋㅋㅋㅋ

 

---

 

Innovative Partnership:

 

-BioNTech Continues to Build Pipeline with First Deal of 2024

-CRISPR pioneer Doudna allies with Danaher for gene editing center targeting rare disease

-JPM24’s Medtech Tidbits: Acquisitions, approvals, analysis and more

-Novartis dances into JPM with $250M Calypso buyout, $185M RNAi alliance

-Senti Bio cuts 37% of staff; Evotec pockets $25M milestone from BMS; Novartis buys SanReno

 

 

FDA Announcements:

 

-Madrigal says it's 'well on the way' to potential NASH launch ahead of FDA decision: #JPM24

-FDA develops pilot to harmonize international gene therapy regulations

-FDA determines GLP-1s not linked to suicidal thoughts or actions in preliminary review

-FDA's Peter Marks says some secondary cancer cases after CAR-T therapy may be 'causal,' but benefits still outweigh risks: #JPM24

 

 

Additional developments in the healthcare sector:

 

-Vertex founder Joshua Boger on surviving downturns, 'painful' partnerships, and the importance of culture: #JPM24

-JPM 2024: AZ, Ginkgo and Moderna Provides Business Updates, Illustrating Optimistic Prospects

U.S. District Court Issues Decision on REGENXBIO and University of Pennsylvania NAV® Technology Patent Infringement Lawsuit

-Bluebird bio's Lyfgenia launch progresses with 2nd major outcomes-based coverage deal

 

 

 

그건 그렇고, CGT쪽 스타트업 펀딩은 좀 줄어드는 추세인가보다 🤑